Latest Headlines

  1. Quanterix To Acquire Akoya Biosciences, Creating The First Integrated Solution For Ultra-Sensitive Detection Of Blood- And Tissue-Based Protein Biomarkers 1/10/2025

    Quanterix Corporation, a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences, The Spatial Biology Company, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction.

  2. QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities To Gain Deeper Insights From Biological Samples 1/10/2025

    QIAGEN (Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analyzed from a single biological sample.

  3. Anbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision And Efficiency 1/9/2025

    Anbio Biotechnology ("Anbio"), a global leader in diagnostics innovation, announces the launch of its Dry Chemiluminescence Immunoassay (CLIA) Solution ADL-1000, a transformative technology designed to deliver rapid, reliable, and cost-effective diagnostic results.

  4. Biofidelity And Cellcarta Partner To Deploy Aspyre® Lung In Global Clinical Trials 1/9/2025

    Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical companies seeking precision medicine solutions, today announced a strategic partnership agreement to utilize Biofidelity's Aspyre® Lung in global clinical trials.

  5. ATCC Announces Award From NCI To Support Research And Vaccine Development For Cancer And HIV 1/9/2025

    ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a five-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract with a ceiling value of $4,055,500 by the National Cancer Institute (NCI).

  6. Viralgen Partners With Vallabh/Minikel Lab And Deverman Lab At The Broad Institute To Advance Gene Therapy Manufacturing Hope For Prion Disease 1/8/2025

    Viralgen and two labs based in the Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard University have partnered to develop and manufacture an innovative approach to gene therapy for prion disease.

  7. Leica Biosystems And Indica Labs Announce Significant Strategic Investment And Creation Of Digital Pathology Platform 1/8/2025

    Leica Biosystems, a global leader in anatomic and digital pathology solutions, and Indica Labs, a global leader in artificial intelligence (AI)-powered digital pathology software, today announced that Leica Biosystems has agreed to make a significant strategic investment in Indica Labs.

  8. ClearNote Health's Avantect Multi-Cancer Detection Test Selected As One Of Two Noninvasive Blood-Based Technologies For National Cancer Institute's Vanguard Study 1/7/2025

    ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that its Avantect Multi-Cancer Detection Test was selected for the Vanguard Study funded by the National Cancer Institute (NCI), part of the National Institutes of Health.

  9. Northlane Capital Partners Invests In United States Drug Testing Laboratories 1/7/2025

    Northlane Capital Partners (“NCP”) announced today that it has invested in United States Drug Testing Laboratories Inc. (“USDTL”), a forensic toxicology laboratory testing for alcohol and substance use. NCP invested alongside USDTL’s management team and its founders, Veronica and Doug Lewis.

  10. Canyon Labs Announces Strategic Acquisition Of iuvo Bioscience's Lab Services And Consulting Businesses To Expand End-To-End Development Solutions 1/7/2025

    Canyon Labs, a global leader in analytical & packaging lab testing and consulting for medical devices and pharmaceuticals, and iuvo BioScience, a full service provider of ophthalmic medical device and pharmaceutical clinical research services, today announced a strategic acquisition that strengthens both organizations' market positions.